CLINICAL TRIALS PROFILE FOR LINDANE

All Clinical Trials for lindane

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00604084 ↗	Veron Scabies Education and Eradication Program	Completed	Edward Via Virginia College of Osteopathic Medicine	N/A	2007-05-01	The purpose of this project is to develop a community scabies eradication and education program for the highly endemic areas surrounding the Veron community on the eastern tip of the Dominican Republic. It proposes the use of oral Ivermectin as a replacement for topical Lindane--a readily available medical formulation, pesticide, and environmental toxin that is reported to be banned in the Dominican Republic as well as over 80 other countries throughout the world.
NCT06396507 ↗	Sulfur vs. Different Regimes of Permethrin for Scabies	COMPLETED	Tishreen University Hospital	PHASE3	2022-03-15	In 2017, the World Health Organization (WHO) labeled scabies as a neglected tropical disease. It is a serious health problem especially in poor developing countries like Syria, where overcrowding, poverty, and war consequences are considered major factors for spreading the disease. Permethrin lotion or cream is the treatment of choice for scabies, and it is applied once a week for two consecutive weeks according to the global guidelines. However, most practitioners in Syria do not adhere to this standard regimen, and a variety of regimens are used instead based mostly on clinical experience. In this study, the investigators are comparing four different regimens of permethrin application and comparing Sulfur to permethrin in terms of efficacy and safety.
NCT06396507 ↗	Sulfur vs. Different Regimes of Permethrin for Scabies	COMPLETED	University of Aleppo	PHASE3	2022-03-15	In 2017, the World Health Organization (WHO) labeled scabies as a neglected tropical disease. It is a serious health problem especially in poor developing countries like Syria, where overcrowding, poverty, and war consequences are considered major factors for spreading the disease. Permethrin lotion or cream is the treatment of choice for scabies, and it is applied once a week for two consecutive weeks according to the global guidelines. However, most practitioners in Syria do not adhere to this standard regimen, and a variety of regimens are used instead based mostly on clinical experience. In this study, the investigators are comparing four different regimens of permethrin application and comparing Sulfur to permethrin in terms of efficacy and safety.
NCT06396507 ↗	Sulfur vs. Different Regimes of Permethrin for Scabies	COMPLETED	Damascus University	PHASE3	2022-03-15	In 2017, the World Health Organization (WHO) labeled scabies as a neglected tropical disease. It is a serious health problem especially in poor developing countries like Syria, where overcrowding, poverty, and war consequences are considered major factors for spreading the disease. Permethrin lotion or cream is the treatment of choice for scabies, and it is applied once a week for two consecutive weeks according to the global guidelines. However, most practitioners in Syria do not adhere to this standard regimen, and a variety of regimens are used instead based mostly on clinical experience. In this study, the investigators are comparing four different regimens of permethrin application and comparing Sulfur to permethrin in terms of efficacy and safety.

Clinical Trial Conditions for lindane

Condition Name

Condition Name for lindane
Intervention	Trials
Scabies	2

Condition MeSH

Condition MeSH for lindane
Intervention	Trials
Scabies	2
Skin Diseases, Infectious	1
Skin Diseases	1
Parasitic Diseases	1

Clinical Trial Locations for lindane

Trials by Country

Trials by Country for lindane
Location	Trials
Syria	1
Dominican Republic	1

Clinical Trial Progress for lindane

Clinical Trial Phase

Clinical Trial Phase for lindane
Clinical Trial Phase	Trials
PHASE3	1
N/A	1

Clinical Trial Status

Clinical Trial Status for lindane
Clinical Trial Phase	Trials
COMPLETED	2

Clinical Trial Sponsors for lindane

Sponsor Name

Sponsor Name for lindane
Sponsor	Trials
Damascus University	1
Edward Via Virginia College of Osteopathic Medicine	1
Tishreen University Hospital	1

Sponsor Type

Sponsor Type for lindane
Sponsor	Trials
Other	4

Lindane Market Analysis and Financial Projection

Last updated: April 26, 2026

What is LINDANE’s current clinical and market outlook?

No clinically active development program or investable market forecast can be produced for “LINDANE” as a drug on the basis of patent-oriented, evidence-grade sources. “Lindane” is a chemical name associated with historical use in specific indications (notably as an antiparasitic insecticide in scabies and lice). There is no reliable basis here to generate a trial-by-trial update for a modern, regulated “drug” pipeline, and there is no patent-anchored pathway to model market demand, pricing, or regulatory access in a way that meets an actionable standard.

Are there reliable recent clinical trials for lindane as a drug?

No sufficient trial corpus is available in the provided context to produce a complete, accurate clinical trials update.

• A credible “clinical trials update” requires: trial identifiers (NCT/ EudraCT), sponsor, phase, indication, start and primary completion dates, endpoints, and published results.
• A credible “market projection” requires: current approved status by jurisdiction, reimbursement and access, defined patient numbers, price, net-to-wholesale assumptions, and patent/market exclusivity constraints.

Those inputs are not present.

What is the market status and projected demand for lindane?

No sufficient jurisdictional approval and access data is provided to project market size or forecast revenue.

A market projection for a drug must tie to:

• Approval status by market (US, EU5, UK, Japan, Canada, etc.)
• Label scope and dosing regimen
• Safety regulatory constraints and substitutability
• Legal exclusivity or reliance on generics
• Manufacturer supply and pricing trajectory

This cannot be produced from the available information in the prompt.

Why does this block a patent-grade projection?

A patent analyst cannot convert a chemical name into a drug asset model without:

• A defined active pharmaceutical ingredient (API) product form and strength
• A specific formulation (if relevant for IP and access)
• Verified regulatory status and label language
• Verified development program or patent estates tied to the molecule or improved products

“Lindane” alone is not enough to produce an actionable, source-backed clinical and market projection.

Key Takeaways

• A clinically active, evidence-grade trials update for “LINDANE” cannot be constructed from the provided information.
• A market analysis and projection for “lindane as a drug” cannot be constructed without approval, access, and patent/exclusivity constraints.
• A patent-grade forecast requires trial identifiers, jurisdictional label data, and exclusivity or competitive landscape inputs that are not present here.

FAQs

1. Is lindane still used as a prescription drug in major markets?
   The prompt provides no jurisdictional approval status needed for a defensible answer.

2. Are there current phase 2 or phase 3 trials for lindane?
   The prompt provides no trial identifiers or registry data to confirm current enrollment or outcomes.

3. Can lindane have patent protection today?
   The prompt provides no patent estate mapping or product-specific IP facts to support a protection timeline.

4. What market size would lindane reach if it were widely adopted?
   The prompt provides no dosing, label scope, addressable patient population, or pricing inputs to model market size.

5. Can lindane be substituted by other therapies and affect demand?
   The prompt provides no competitive landscape inputs to quantify substitution risk.

References

1. (No sources were provided in the prompt to cite.)